Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HR070803 + oxaliplatin + 5-fluorouracil + calcium folinate + bevacizumab
- Development stage
- Unknown
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HR070803 + oxaliplatin + 5-fluorouracil + calcium folinate + bevacizumab is a multi-agent chemotherapeutic regimen, where HR070803 is a novel liposomal formulation of irinotecan. This combination is under investigation primarily for first-line treatment of unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma (PDAC)[1][3]. HR070803 delivers irinotecan in a liposomal form for prolonged circulation and slow release, improving delivery and tolerability[1][3]. Oxaliplatin is a platinum-based cytotoxic agent that forms DNA crosslinks, leading to apoptosis. 5-fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. Calcium folinate (leucovorin) enhances the cytotoxicity of 5-FU. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting tumor angiogenesis[2][6].
- Other names
- irinotecan liposome + oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab
02
Targets
Beyond the preview
Go deeper on HR070803 + oxaliplatin + 5-fluorouracil + calcium folinate + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HR070803 + oxaliplatin + 5-fluorouracil + calcium folinate + bevacizumab.